tiprankstipranks
Trending News
More News >
CryoPort Inc (CYRX)
NASDAQ:CYRX
Advertisement

CryoPort (CYRX) AI Stock Analysis

Compare
637 Followers

Top Page

CYRX

CryoPort

(NASDAQ:CYRX)

Rating:68Neutral
Price Target:
$9.50
▲(7.22% Upside)
CryoPort's overall stock score reflects a mix of significant financial challenges and promising strategic initiatives. The company's financial performance is a major concern due to persistent losses and negative cash flows. However, strong technical indicators, attractive valuation, and positive earnings call sentiment provide a counterbalance. The strategic partnership with DHL further enhances the company's growth prospects, contributing to a moderately positive outlook.
Positive Factors
Financial Performance
Strong broad-based beat in the quarter highlights improvement, with revenue ahead of expectations.
Market Position
CYRX holds a dominant market-leading position in C&GT services with 70% market share.
Strategic Divestitures
Recent sale of CryoPDP to DHL effectively removes a major cash runway overhang on shares, with the company now well capitalized.
Negative Factors
Regulatory Environment
The full impact of policy changes, including broad-based tariffs and new FDA leadership, is not yet reflected in the current results.

CryoPort (CYRX) vs. SPDR S&P 500 ETF (SPY)

CryoPort Business Overview & Revenue Model

Company DescriptionCryoPort, Inc. (CYRX) is a logistics company specializing in temperature-controlled supply chain solutions for the life sciences sector. The company primarily serves the biopharmaceutical, cell and gene therapy, and regenerative medicine industries by providing innovative shipping solutions that ensure the integrity and viability of sensitive biological materials. CryoPort's core products include cryogenic shipping solutions, data monitoring systems, and a range of temperature-controlled packaging options designed to meet the rigorous demands of transporting critical biological samples.
How the Company Makes MoneyCryoPort generates revenue through various streams primarily focused on its temperature-controlled shipping solutions. The company earns money by providing specialized packaging and shipping services that cater specifically to the needs of the biopharmaceutical and life sciences industries. Key revenue streams include fees for shipping services, sales of proprietary packaging products, and monitoring services that ensure compliance with regulatory standards. Additionally, CryoPort has established significant partnerships with major biopharmaceutical companies and clinical research organizations, which contribute to its earnings by securing long-term contracts and expanding its service offerings in the rapidly growing market for cell and gene therapies.

CryoPort Earnings Call Summary

Earnings Call Date:Aug 05, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Positive
Cryoport's earnings call reflects strong revenue growth and strategic advancements, particularly through the DHL partnership, despite some challenges with a client's therapy pause and regulatory setbacks. The overall business outlook remains positive with continued focus on innovation and global expansion.
Q2-2025 Updates
Positive Updates
Strong Revenue Growth
Cryoport reported a 14% increase in total revenue from operations for the second quarter, with a 21% year-over-year increase in service revenue and a 33% increase in revenue from commercial cell and gene therapies.
Successful Strategic Partnership with DHL
Cryoport launched a strategic partnership agreement with DHL Group, including a $200 million cash infusion from the sale of CRYOPDP to DHL, enhancing global bio logistics capabilities.
Increased Clinical Trial Support
Cryoport supported a record 728 clinical trials, approximately 70% of the industry cell and gene therapy trials, with the expectation of up to 20 application filings and one new therapy approval for the remainder of 2025.
Product Innovation
Launch of next-generation MVE SC 4/2 and SC 4/3 vapor shippers and MVE's high-efficiency 800-seat cryogenic storage system, supporting improved safety and reliability in transporting sensitive biological materials.
Improved Financial Metrics
Significant increase in gross margin and a meaningful lift in adjusted EBITDA due to profitability initiatives, with a reported 47% total gross margin.
Negative Updates
Client Therapy Pause
A gene therapy client temporarily paused distribution, affecting revenue by an estimated $2 million for the remainder of the year.
Regulatory Challenges
Five clients encountered negative opinions from the FDA or MAA regarding their therapy filings, potentially impacting future approvals.
China Market Stagnation
No expected market expansion or recovery in China for 2025, with continued monitoring of government stimulus programs.
Company Guidance
During Cryoport's second quarter 2025 earnings call, the company reported strong financial performance, highlighting a 21% year-over-year increase in service revenue, which accounted for 54% of total revenue from continuing operations. Key growth areas included a 33% rise in revenue from commercial cell and gene therapies and a 28% increase in BioStorage/BioServices. The Life Sciences products segment saw an 8% year-over-year revenue growth, driven by demand from animal health customers. Overall, total revenue from operations increased by 14%, with improvements in gross margin and adjusted EBITDA. Despite a temporary pause in distribution by a gene therapy client, Cryoport reaffirmed its full-year 2025 revenue guidance, citing broad support for 728 clinical trials and the strategic partnership with DHL Group as significant drivers of future growth.

CryoPort Financial Statement Overview

Summary
CryoPort faces significant financial challenges across its income statement, balance sheet, and cash flow. Despite a solid gross profit margin, persistent net losses and negative cash flows indicate operational inefficiencies and financial instability. The improvement in leverage metrics provides some positive outlook, but overall, CryoPort needs to address its profitability and cash management to achieve sustainable growth and financial health.
Income Statement
35
Negative
CryoPort's income statement reflects significant challenges. The company has experienced declining revenues from $237.3 million in 2022 to $214.8 million in the TTM period ending March 2025. Despite a healthy gross profit margin of approximately 42.9% in TTM, the company struggles with negative EBIT and net income margins, indicating consistent operating and net losses. The TTM net profit margin is -50.2%, a deterioration from -15.7% in 2022, highlighting worsening profitability.
Balance Sheet
55
Neutral
CryoPort's balance sheet shows mixed signals. The debt-to-equity ratio has improved slightly to 0.61 in TTM from 0.78 in 2022, indicating a reduction in leverage, but the company's equity ratio has decreased to 57.0%, reflecting reduced equity relative to assets. The return on equity remains negative due to ongoing losses, with a TTM ROE of approximately -27.0%. The balance sheet displays adequate liquidity with $244 million in cash and short-term investments, though overall financial stability is challenged by recurring losses.
Cash Flow
40
Negative
CryoPort's cash flow statement is concerning, with negative operating and free cash flows. The TTM operating cash flow is -$17.4 million, further stressing financial operations. Free cash flow is also negative at -$34.4 million, indicating insufficient cash generation to cover capital expenditures. The free cash flow to net income ratio remains below 1, demonstrating cash flow struggles in tandem with net losses.
BreakdownTTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income Statement
Total Revenue214.83M228.38M233.25M237.28M222.61M78.70M
Gross Profit92.20M99.63M99.33M103.87M96.58M36.33M
EBITDA-69.31M-78.61M-66.36M-6.19M-248.91M-20.31M
Net Income-107.84M-114.76M-99.59M-37.33M-275.53M-32.69M
Balance Sheet
Total Assets699.84M703.49M957.74M1.04B1.11B552.40M
Cash, Cash Equivalents and Short-Term Investments244.03M261.75M456.75M523.32M628.80M93.32M
Total Debt242.67M250.70M416.00M435.91M427.06M130.92M
Total Liabilities301.03M301.59M468.72M482.91M471.14M169.71M
Stockholders Equity398.81M401.90M489.02M555.84M641.83M382.70M
Cash Flow
Free Cash Flow-34.39M-33.58M-45.66M-26.05M-16.88M-24.54M
Operating Cash Flow-17.40M-16.32M-757.00K-1.85M8.13M-14.87M
Investing Cash Flow176.29M176.81M36.05M-59.68M-469.25M-382.31M
Financing Cash Flow-162.23M-161.53M-23.80M-39.17M564.34M385.58M

CryoPort Technical Analysis

Technical Analysis Sentiment
Positive
Last Price8.86
Price Trends
50DMA
7.81
Positive
100DMA
6.97
Positive
200DMA
7.02
Positive
Market Momentum
MACD
0.33
Positive
RSI
58.38
Neutral
STOCH
51.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYRX, the sentiment is Positive. The current price of 8.86 is above the 20-day moving average (MA) of 8.45, above the 50-day MA of 7.81, and above the 200-day MA of 7.02, indicating a bullish trend. The MACD of 0.33 indicates Positive momentum. The RSI at 58.38 is Neutral, neither overbought nor oversold. The STOCH value of 51.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CYRX.

CryoPort Risk Analysis

CryoPort disclosed 33 risk factors in its most recent earnings report. CryoPort reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

CryoPort Peers Comparison

Overall Rating
UnderperformOutperform
Sector (64)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
$443.59M6.07-8.50%-10.16%73.08%
64
Neutral
$10.72B16.047.75%2.00%2.65%-15.66%
64
Neutral
$305.02M18.388.09%7.18%186.98%
55
Neutral
$164.14M-23.18%49.48%80.17%
54
Neutral
$924.68M-78.76%0.86%30.12%79.23%
49
Neutral
$59.13M-790.22%5.14%-17.39%
47
Neutral
$228.33M124.65-43.30%-10.97%-696.45%
* Industrials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CYRX
CryoPort
8.86
0.19
2.19%
AIRT
Air T
21.88
-0.72
-3.19%
FWRD
Forward Air
30.03
-2.21
-6.85%
RLGT
Radiant Logistics
6.47
0.41
6.77%
CRGO
Freightos Limited
3.28
1.71
108.92%
FLX
BingEx Ltd. ADR
3.21
-13.28
-80.53%

CryoPort Corporate Events

M&A TransactionsBusiness Operations and Strategy
CryoPort Sells CRYOPDP Business to DHL Group
Positive
Jun 13, 2025

On June 11, 2025, Cryoport, Inc. completed the divestiture of its CRYOPDP Business to DHL Group for approximately $200 million, as part of a strategic move to enhance its core capabilities and focus on the rapidly growing regenerative medicine market. This transaction, along with a newly formed strategic partnership with DHL, is expected to strengthen Cryoport’s positioning in the Asia Pacific and EMEA regions, offering enhanced supply chain services and contributing to the company’s long-term profitability goals.

The most recent analyst rating on (CYRX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on CryoPort stock, see the CYRX Stock Forecast page.

Executive/Board ChangesShareholder Meetings
CryoPort Holds 2025 Annual Stockholders Meeting
Neutral
Jun 10, 2025

On June 6, 2025, Cryoport, Inc. held its 2025 Annual Meeting of Stockholders, where several key proposals were voted on. The election of directors resulted in the appointment of six individuals to serve until the 2026 Annual Meeting. Additionally, the appointment of Deloitte and Touche LLP as the independent registered public accounting firm was ratified. Stockholders also approved the compensation of the company’s named executive officers and decided to hold an advisory vote on this compensation annually.

The most recent analyst rating on (CYRX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on CryoPort stock, see the CYRX Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 07, 2025